Summary:
The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.
Qualified Participants Must:
• Male or female patients 18 to 65 years of age (inclusive)
•
Diagnosed with bipolar I disorder, manic or mixed-type, per DSM-5 criteria
•
Voluntary hospitalization for current manic episode
Qualified Participants May Receive:
Monetary compensation for participation.